Spruce biosciences to participate in may investor conferences

San francisco--(business wire)--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in may. rbc capital markets global healthcare conference date: may 17-18, 2022 format: fireside chat (may 17 at 10:00 a.m. et) and 1x1 meetings h.c. wainwright global investment conference date: may 23-26, 2022 format: company presentation (may 25 at 4:00 p.m. et) and 1x1 meetings interested parties can access the webcast for each conference presentation from the events section of the company’s investor relations website at https://investors.sprucebiosciences.com. a replay of the webcasts will be available after the conclusion of the live presentations for approximately 30 days. about spruce biosciences spruce biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. spruce is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (cah). classic cah is a serious and life-threatening disease with no known novel therapies approved in approximately 50 years. spruce is also developing tildacerfont for women suffering from polycystic ovary syndrome (pcos) with primary adrenal androgen excess. to learn more, visit www.sprucebiosciences.com and follow us on twitter @spruce_bio, linkedin, facebook and youtube.
SPRB Ratings Summary
SPRB Quant Ranking